Guoxin Securities released a research report on April 26 stating that it gave Proplo Pharmaceutical (000739.SZ) a purchase rating. The main reasons for the rating include: 1) Under the high base of the same period in 2023, the company achieved double growth in revenue and profit in the first quarter of 2024; 2) APIs and intermediates sector: revenue increased year-on-year, and gross margin declined; 3) CDMO sector: project growth continued, revenue declined under a high base; 4) formulation sector: R&D investment increased, and the pace of application and approval is expected to accelerate. (Mainichi Keizai Shimbun)
国信证券4月26日发布研报称，给予普洛药业（000739.SZ）买入评级。评级理由主要包括：1）在2023年同期高基数下，公司2024年一季度收入、利润实现双增长；2）原料药及中间体板块：收入同比增长，毛利率有所下滑；3）CDMO板块：项目增长态势持续，高基数下收入下滑；4）制剂板块：研发投入加大，申报及获批节奏有望提速。（每日经济新闻）
Guoxin Securities released a research report on April 26 stating that it gave Proplo Pharmaceutical (000739.SZ) a purchase rating. The main reasons for the rating include: 1) Under the high base of the same period in 2023, the company achieved double grow
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated